Stryker (SYK) Stock Overview
Operates as a medical technology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
SYK Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Stryker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$360.13 |
| 52 Week High | US$406.19 |
| 52 Week Low | US$329.16 |
| Beta | 0.90 |
| 1 Month Change | -3.82% |
| 3 Month Change | -7.64% |
| 1 Year Change | -7.52% |
| 3 Year Change | 60.31% |
| 5 Year Change | 54.56% |
| Change since IPO | 66,385.50% |
Recent News & Updates
Recent updates
Stryker: Striking Again
Nov 03Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Sep 08
Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
Aug 08
Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)
Jul 09With Stryker Corporation (NYSE:SYK) It Looks Like You'll Get What You Pay For
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at Stryker Corporation (NYSE:SYK)
May 02Stryker (NYSE:SYK) Has A Rock Solid Balance Sheet
May 01Calculating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)
Apr 07Stryker Corporation's (NYSE:SYK) Share Price Matching Investor Opinion
Mar 16Is Stryker Corporation (NYSE:SYK) Potentially Undervalued?
Feb 26There May Be Some Bright Spots In Stryker's (NYSE:SYK) Earnings
Feb 05Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Jan 27Here's Why We Think Stryker (NYSE:SYK) Is Well Worth Watching
Jan 17Stryker: Starting 2025 With A Bolt-On Deal For Inari Medical
Jan 08We Think Stryker (NYSE:SYK) Can Stay On Top Of Its Debt
Dec 26Stryker Corporation: A Wide-Moat Medical Device Company, But Overvalued
Dec 24Stryker (NYSE:SYK) Is Paying Out A Larger Dividend Than Last Year
Dec 13Investor Optimism Abounds Stryker Corporation (NYSE:SYK) But Growth Is Lacking
Dec 03At US$386, Is It Time To Put Stryker Corporation (NYSE:SYK) On Your Watch List?
Nov 21Stryker's Growth Via Continuous Acquisitions Led To Declining ROIC
Oct 16Stryker: Wait For A Better Entry Point Post-Q2 Results
Aug 06Shareholder Returns
| SYK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.4% | 0.09% | -2.7% |
| 1Y | -7.5% | 0.4% | 11.9% |
Return vs Industry: SYK underperformed the US Medical Equipment industry which returned 0.4% over the past year.
Return vs Market: SYK underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SYK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 53,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
Stryker Corporation Fundamentals Summary
| SYK fundamental statistics | |
|---|---|
| Market cap | US$138.52b |
| Earnings (TTM) | US$2.94b |
| Revenue (TTM) | US$24.38b |
Is SYK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYK income statement (TTM) | |
|---|---|
| Revenue | US$24.38b |
| Cost of Revenue | US$8.52b |
| Gross Profit | US$15.86b |
| Other Expenses | US$12.92b |
| Earnings | US$2.94b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.70 |
| Gross Margin | 65.05% |
| Net Profit Margin | 12.07% |
| Debt/Equity Ratio | 76.2% |
How did SYK perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 14:49 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stryker Corporation is covered by 59 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |